Le centre hospitalier de Perpignan, anciennement hôpital Saint-Jean, est un centre hospitalier situé à Perpignan dans les Pyrénées-Orientales, en région Occitanie.

During the past decade, CH Perpignan conducted 75 clinical trials. In the 10-year time frame, 75 clinical trials started and 11 clinical trials were completed, i.e. on average, 14.7% percent of trials that started reached the finish line to date. In the past 5 years, 31 clinical trials started and 5 clinical trials were completed. i.e. 16.1% of trials that started reached the finish line.

Out of the total clinical trials conducted in "CH Perpignan" #1 sponsor was "Groupe Francophone des Myelodysplasies" with 13 trials, followed by "Federation Francophone de Cancerologie Digestive" with 11 trials sponsored, "The Lymphoma Academic Research Organisation" with 11 trials sponsored, "Centre Hospitalier Universitaire de Nīmes" with 9 trials sponsored and "UNICANCER" with 9 trials sponsored. Other sponsors include 70 different institutions and companies that sponsored additional 52 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "CH Perpignan" #1 collaborator was "Celgene Corporation" with 3 trials as a collaborator, "Janssen-Cilag Ltd." with 3 trials as a collaborator, "Amgen" with 2 trials as a collaborator, "Breast International Group" with 2 trials as a collaborator and "Celgene" with 2 trials as a collaborator. Other collaborators include 114 different institutions and companies that were collaborators in the rest 114 trials.

According to Clinical.Site data, the most researched conditions in "CH Perpignan" are "Myelodysplastic Syndromes" (7 trials), "Multiple Myeloma" (5 trials), "MDS" (4 trials), "Acute Myeloid Leukemia" (3 trials) and "Breast Cancer" (3 trials). Many other conditions were trialed in "CH Perpignan" in a lesser frequency.

Most popular intervention types in "CH Perpignan" are "Drug" (80 trials), "Other" (18 trials), "Procedure" (10 trials), "Device" (7 trials) and "Biological" (4 trials). Other intervention types were less common.

The name of intervention was led by "Rituximab" (10 trials), "Cyclophosphamide" (7 trials), "Lenalidomide" (6 trials), "Azacitidine" (4 trials) and "Bendamustine" (4 trials). Other intervention names were less common.

The vast majority of trials in "CH Perpignan" are 118 trials for "All" genders and 7 trials for "Female" genders.

Currently, there are NaN active trials in "CH Perpignan". 2 are not yet recruiting, 30 are recruiting, 14 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 59 completed trials in CH Perpignan, undefined suspended trials, and 10 terminated clinical trials to date.

Out of the total trials that were conducted in CH Perpignan, 5 "Phase 1" clinical trials were conducted, 41 "Phase 2" clinical trials and 37 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 17 trials that are defined as “Not Applicable".

CH Perpignan has several departments that took part in Clinical trials: "PERPIGNAN - CH St Jean - Hématologie Clinique" - 2 trials, "CH Perpignan, Nephrology department" - 2 trials, "Hopital Saint Jean; Centre Henri Pujol" - 2 trials